COCP COCRYSTAL PHARMA INC revenue, earnings and financials
For the quarter ended June 30, 2026, COCRYSTAL PHARMA INC reported revenue of $105K, net income of −$3.16M and diluted EPS of −$0.23; for the fiscal year ended December 2025 revenue was n/a.
COCP annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$9.02M, net income −$8.83M (margin n/a), EPS −$0.78
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$17.9M, net income −$17.5M (margin n/a), EPS −$1.72
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$18.6M, net income −$18.0M (margin n/a), EPS −$1.87
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$38.8M, net income −$38.8M (margin n/a), EPS −$4.77
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$14.2M, net income −$14.2M (margin n/a), EPS −$0.16
COCP quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $105K, net income −$3.16M, EPS −$0.23
- Quarter ended Mar 31, 2026: revenue $225K, net income −$2.30M, EPS −$0.17
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$2.43M, EPS −$0.16
- Quarter ended Sep 30, 2025: revenue n/a, net income −$2.05M, EPS −$0.19
- Quarter ended Jun 30, 2025: revenue n/a, net income −$2.06M, EPS −$0.20
- Quarter ended Mar 31, 2025: revenue n/a, net income −$2.30M, EPS −$0.23
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$3.27M, EPS −$0.31
- Quarter ended Sep 30, 2024: revenue n/a, net income −$4.94M, EPS −$0.49
- Quarter ended Jun 30, 2024: revenue n/a, net income −$5.34M, EPS −$0.53
- Quarter ended Mar 31, 2024: revenue n/a, net income −$3.96M, EPS −$0.39
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$4.46M, EPS −$0.41
- Quarter ended Sep 30, 2023: revenue n/a, net income −$4.17M, EPS −$0.41
- Quarter ended Jun 30, 2023: revenue n/a, net income −$4.17M, EPS −$0.41
- Quarter ended Mar 31, 2023: revenue n/a, net income −$5.19M, EPS −$0.64
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$4.50M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$5.70M, EPS −$0.70
- Quarter ended Jun 30, 2022: revenue n/a, net income −$24.4M, EPS −$3.00
- Quarter ended Mar 31, 2022: revenue n/a, net income −$4.21M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$3.69M, EPS −$0.04
- Quarter ended Sep 30, 2021: revenue n/a, net income −$3.94M, EPS −$0.04
COCP cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$8.19M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$16.5M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$14.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$21.4M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$12.7M, share buybacks n/a
COCP balance sheet
- Jun 30, 2026: cash n/a, total assets $4.65M, total liabilities $3.61M, shareholders' equity $1.04M
- Mar 31, 2026: cash n/a, total assets $7.43M, total liabilities $3.31M, shareholders' equity $4.12M
- Dec 31, 2025: cash $7.03M, total assets $9.71M, total liabilities $3.38M, shareholders' equity $6.33M
- Sep 30, 2025: cash n/a, total assets $10.4M, total liabilities $2.78M, shareholders' equity $7.67M
- Jun 30, 2025: cash n/a, total assets $8.51M, total liabilities $3.17M, shareholders' equity $5.33M
- Mar 31, 2025: cash n/a, total assets $10.7M, total liabilities $3.36M, shareholders' equity $7.30M
- Dec 31, 2024: cash $9.86M, total assets $13.5M, total liabilities $3.93M, shareholders' equity $9.52M
- Sep 30, 2024: cash n/a, total assets $16.2M, total liabilities $3.53M, shareholders' equity $12.7M
Is COCP profitable?
No. COCRYSTAL PHARMA INC lost $9.94M over the last four quarters.
What is COCP's EPS?
Diluted earnings per share over the last four quarters were −$0.75; −$0.23 in the latest quarter.